Track regulatory status, clinical trials, and published research across three jurisdictions.
Compound status overview
185+ compounds tracked across 3 jurisdictions
Research Landscape
Featured Compound
GLP-1 Receptor Agonist
Semaglutide is a once-weekly injection (sold as Ozempic for diabetes and Wegovy for weight management) or daily tablet (Rybelsus for diabetes) that mimics GLP-1, a natural gut hormone that controls blood sugar and appetite. It has become one of the most widely discussed medications in the world, with clinical trial data spanning over 50,000…
Regulatory Timeline
FDA ORIG 1
FDA SUPPL 1
FDA ORIG 1
FDA SUPPL 4
FDA SUPPL 3
FDA SUPPL 1
FDA SUPPL 8
FDA SUPPL 6
Latest Articles
Short circulating half-lives remain one of the central obstacles in peptide drug development, with renal filtration and proteolytic degradation clearing most unmodified peptides within minutes to hours. N-terminal chemical modifications—including albumin-binding peptide domains, Fc fusion constructs, and emerging transthyretin-binding motifs—offer mechanistically distinct routes to extending plasma residence time. This article examines the structural design principles, comparative preclinical ph
Glucagon-like peptide-1 (GLP-1) based compounds span a structural continuum from near-native peptide sequences to heavily engineered variants incorporating non-natural amino acids, fatty acid conjugates, and albumin-binding domains. These modifications produce measurable differences in receptor binding kinetics, metabolic stability, and potency profiles in preclinical models. Understanding the mechanistic basis for this structural diversity clarifies why chemically distinct compounds targeting t
A Certificate of Analysis for a research peptide conveys far more than a single purity percentage. Understanding the analytical methods behind that number—HPLC conditions, mass spectrometry confirmation, endotoxin assay results, and water content data—is essential for assessing whether a compound is suitable for reliable preclinical work. This guide explains how to read CoA documents critically and what questions to ask when the data falls short.
Clinical Trial Spotlight
Tirzepatide
Eli Lilly has announced positive topline results from its Phase III SUMMIT trial evaluating tirzepatide in patients with heart failure with preserved ejection fraction and obesity. The trial met its primary endpoint demonstrating statistically significant improvement in heart failure symptoms.
Trials by phase
Platform at a Glance
185
Compounds
13,277
Clinical Trials
1,288
Recruiting
446,936
Publications
Latest updates
Trial results posted for Cyclosporine
Trial status changed for Oxytocin
News & updates
Results posted for trial NCT05041426: Letermovir for CMV Prevention After Lung Transplantation.
Read more →Trial NCT04523922 status changed from recruiting to active not recruiting.
Read more →Trial NCT04547049 status changed from recruiting to active not recruiting.
Read more →Results posted for trial NCT03361735: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer.
Read more →Trial NCT07403604 status changed from not yet recruiting to recruiting.
Read more →Trial NCT04433156 status changed from unknown to completed.
Read more →Trial NCT03984097 status changed from active not recruiting to completed.
Read more →Results posted for trial NCT03361735: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer.
Read more →